government site. Those leading to excess bone deposition are considered osteoblastic. Nevertheless, they do not appear to function in the osteoclast resorption lacuna, probably due to the low pH in this compartment. In middle aged and elderly women, calcium and/or vitamin D deficiencies are quite common, as is the incidence of breast cancer [65]. 2021 Aug;40(34):5314-5326. doi: 10.1038/s41388-021-01931-1. Breast, prostate, and lung cancers represent the main sources of bone metastases, with prostate and lung cancers being most common in males and breast cancer being most common in females . Runx2 also promotes PTHrP expression in breast cancer cells, which in turn stimulates other cells, such as osteoblasts, to produce more RANKL, leading to further osteoclast activation. Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. The role of lining cells. In reality the system is much more complex (Table 1). It should be noted that in addition to obvious members of the vicious cycle, other factors are produced during the process, including inflammatory cytokines, which significantly affect tumor cell survival, cell differentiation, and angiogenesis. Kozlow W, Guise TA: Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. 2022 Aug 6;10(8):1908. doi: 10.3390/biomedicines10081908. 10.3390/ph3030572. In the bone, OPN is involved in the differentiation and activity of osteoclasts, and inhibition of mineral deposition in the osteoid [37]. By using this website, you agree to our Clusters of osteoblasts produce osteoid, composed of collagen, osteonectin, chondroitin sulfate and other non-mineral molecules, which matures and is then mineralized over several months [12]. At first glance it would seem ideal to pair bisphosphonates or denosumab with teriparatide since the former two block bone resorption and the latter stimulates bone deposition. 2006, 6: 181-10.1186/1471-2407-6-181. 10.1177/154405910608500704. 10.1038/35036374. Pharmaceuticals. Cancer Res. This process is effected by osteoblasts and osteoclasts within a functional and anatomic unit known as the basic multicellular unit (BMU). Estrogen profoundly affects bone remodeling by suppressing production of RANKL while increasing production of OPG. Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, Eyre R, Alfrez D, Wilkinson JM, Holen I, Clarke RB, Ottewell P. Breast Cancer Res. Mol Cancer. Thus, Runx2 plays a significant role in the vicious cycle via TGF--induced IHH-PTHrP pathways in breast cancer cells, resulting in increased osteoclastogenesis and osteolysis. Osteoblasts also produce osteoprotegerin (OPG), a decoy receptor to RANKL. Provided by the Springer Nature SharedIt content-sharing initiative. Breast cancer-derived factors facilitate osteolytic bone metastasis. AMM, the senior investigator and corresponding author, has worked in the area of breast cancer metastasis to bone for over 12 years. HHS Vulnerability Disclosure, Help sharing sensitive information, make sure youre on a federal Elazar V, Adwan H, Bauerle T, Rohekar K, Golomb G, Berger MR: Sustained delivery and efficacy of polymeric nanoparticles containing osteopontin and bone sialoprotein antisenses in rats with breast cancer bone metastasis. The entry of breast cancer cells into the bone micro-environment synergistically increases the complexity of cell-cell interactions. Cancer Res. These functional molecules complete the cycle and osteolysis continues. 2010, 115: 140-149. J Dent Res. Clin Breast Cancer. 10.1016/S8756-3282(03)00086-3. 2023;2582:343-353. doi: 10.1007/978-1-0716-2744-0_24. COX-2 inhibition also partially attenuated the ability of two breast cancer cell lines to degrade and invade extracellular matrix components such as laminin and collagen [47]. Pratap and colleagues [40] found that Runx2 responds to TGF- stimulation by activating the expression of Indian hedgehog (IHH), which further increases the level of PTHrP. Corisdeo S, Gyda M, Zaidi M, Moonga BS, Troen BR: New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. 10.1056/NEJMe1010459. Cancer cells also can elicit an increase in osteoblast production of several other osteoclastogenic cytokines, such as monocyte chemotactic protein-1 (MCP-1) and IL-6, IL-8 and TNF [22]. It is impossible to understand the growth and progression of cancer cells in the bone marrow without consideration of the interaction between osteoblasts and osteoclasts. Bookshelf Proff P, Romer P: The molecular mechanism behind bone remodelling: a review. The receptor binding activity in turn causes an increase in production of RANKL. Denosumab (Prolia), the latest drug to enter the field, is a monoclonal antibody to RANKL. Stopeck A: Denosumab findings in metastatic breast cancer. Among these are the MMPs. Unable to load your collection due to an error, Unable to load your delegates due to an error. J Bone Oncol. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. 10.1006/bbrc.2001.5127. Cells of the monocyte-macrophage lineage are stimulated to form osteoclast progenitor cells. osteolytic bone metastases are characterized by destruction and loss of normal bone or bone matrix 1,2 in which parathyroid hormone-related peptide (pthrp) features a significant part in the evolution of osteolytic lesions by stimulating the differentiation and activating osteoclasts via the rankl pathway, which primarily mediate the degradation Recent research has revealed how cancer cell Runx2 affects other cells in the bone microenvironment and promotes osteolysis. These molecules not only help support tumor cells, but also are osteoclastogenic. Exp Cell Res. Google Scholar. Myeloma cells produce factors that upregulate osteoblast production of M-CSF and RANKL and downregulate production of OPG. Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W: A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. CA Cancer J Clin. Continuing research into the mechanisms of cancer cell dormancy could result in a treatment that would prevent cancer cell proliferation in the bone and the chain of events that leads to osteolysis. PTHrP is expressed in the primary tumors of about 50% of patients and in more than 90% of breast cancer bone metastasis samples [18]. In fact, a new drug, denosumab (Prolia), a fully human monoclonal antibody to RANKL, has been approved by the US Food and Drug Administration (FDA) for the treatment of postmenopausal women with high risk of osteoporotic fractures, and is under priority review for patients with bone metastases. Br J Cancer. Miao W, Ti Y, Lu J, Zhao J, Xu B, Chen L, Bao N. Front Chem. In the next step, preosteoblasts are recruited from the mesenchymal stem cell population and differentiate into osteoblasts. There is evidence in both humans and animals that bone loss in osteolytic metastasis is partly due to the failure of the osteoblasts to produce new osteoid for the bone matrix. In addition, factors such as TGF- and IGFs that are released from the bone matrix during degradation serve to increase PTHrP expression in breast cancer cells. They follow the osteoclasts, reforming the bone matrix. In a study by Mercer and Mastro [59], osteoblasts treated with conditioned media from MDA-MB-231 breast cancer cells displayed disorganized F-actin fibrils and reduced focal adhesion plaques. It's the most advanced stage of breast cancer. Ganapathy and colleagues [24] found that TGF- antagonists are able to reduce bone metastasis and the number and activity of differentiated osteoclasts [24]. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer Statistics, 2007. We are in the process of adding osteoclasts to the system to create a rudimentary in vitro bone remodeling unit. Methods Mol Biol. Cathepsin K is believed to be the major protease in this capacity. 10.1210/endo-86-6-1436. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM: Molecular mechanisms of breast cancer metastases to bone. The site is secure. The tumors that develop, sometimes called lesions, can: Make the bones weaker and less dense. 2005, 5 (Suppl): S46-53. It has been suggested that cancer cells preferentially metastasize to bone due to their ability to express genes that are normally considered bone or bone-related [36]. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA: Molecular biology of bone metastasis. SPARC cleavage also coincides with an increase in inflammatory cytokines such as IL-6 and IL-8 [51]. Marie L, Braik D, Abdel-Razeq N, Abu-Fares H, Al-Thunaibat A, Abdel-Razeq H. Cancer Manag Res. 2022 Nov 30;10:1088823. doi: 10.3389/fchem.2022.1088823. Lipton A: Bone continuum of cancer. J Natl Compr Canc Netw. Increased production of EMMPRIN in turn leads to increases in VEGF and MMPs. https://doi.org/10.1186/bcr2781. 2010, 70: 1835-1844. PTH/PTHrP, TNF-, prostaglandins (PGE2), IL-1, IL-11, FGF-2, and IGF-1 have been reported to increase RANKL production. Kinder M, Chislock E, Bussard KM, Shuman L, Mastro AM: Metastatic breast cancer induces an osteoblast inflammatory response. 2001, 142: 5050-5055. Federal government websites often end in .gov or .mil. Google Scholar, Mundy GR: Bone Remodeling and its Disorders. 2010, [Epub ahead of print]. While they are categorized into functional groups, it should be noted that many of these factors are multifunctional and must be considered within the context of the bone remodeling system as a whole. Mol Cancer Ther. These molecules cause osteoblasts not only to form new bone but also to release RANKL and other osteoclastic mediators. PDGF is a dimeric protein consisting of two of four possible subunits. DMS is a senior research technician with many years experience in the bone field. 2010, 70: 412-424. Home; Study Search; Study Details From Other Databases This site needs JavaScript to work properly. Breast cancer cells can spread to the bone through the lymphatic system or the blood. There are conflicting reports regarding their effect on osteoblasts. McHayleh W, Ellerman J, Roodman D: Hematologic malignancies and bone. Assessment; Bone; Bone-targeted therapy; Detection; Mechanism of bone metastases; Metastasis; Therapy. In contrast to breast cancer, prostate bone metastasis often results in osteoblastic lesions. Rucci N, Millimaggi D, Mari M, Del Fattore A, Bologna M, Teti A, Angelucci A, Dolo V: Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. It is now known that PGE2 signaling through its receptor EP4 plays a crucial role in osteolysis by inducing monocytes to form mature osteoclasts. Correspondence to 2007, 57: 43-66. Identification of a stimulator or protector of osteoblasts would be a major improvement in treatment for osteolytic breast cancer as well as other diseases of bone loss. MMPs are involved in the bone remodeling process after osteoclasts are finished. Osteoblastic or blastic metastases cause an area of the bone to look denser or sclerotic. Using this device, we have been able to grow osteoblasts into a mineralized tissue. However, both drugs are associated with low incidence of osteonecrosis of the jaw [75]. Part of Kang and colleagues [20] found that expression of two MMP genes, MMP1 and ADAMTS1, discriminated between a subline of osteotropic metastatic MDA-MB-231 cells and the parental line. These approaches still rely on animals. eCollection 2022 Dec. Edwards CM, Clements ME, Vecchi LA 3rd, Johnson JA, Johnson RW. Heterogeneity of tumor cells in the bone microenvironment: Mechanisms and therapeutic targets for bone metastasis of prostate or breast cancer. This feature accounts for the variable sensitivity and specificity of different imaging modalities. Blood. In this context, RANKL increases in the presence of inflammatory agents from infectious organisms, such as lipopolysaccharide, CpGpDNA and viral double-stranded DNA [41]. Until recently they were the only FDA approved drugs for metastatic bone disease [71]. As might be expected from the nature of the osteolytic process, that is, the degradation of bone, the microenvironment contains many proteases. Those leading to excess bone deposition are considered osteoblastic. Breast cancer metastasis to the bone: mechanisms of bone loss, http://breast-cancer-research.com/series/metastasis_pathway. -. 2010, 2: 907-915. HDAC inhibitors stimulate LIFR when it is repressed by hypoxia or PTHrP in breast cancer. The purpose of this study is to find a safe dose of: - Xentuzumab in combination with abemaciclib - Xentuzumab in combination with abemaciclib and hormonal therapies The study also tests whether these medicines make tumours shrink in participants with lung and breast cancer. Edited by: Rosen CL. PubMed One of its substrates is SPARC (secreted protein acidic and rich in cysteine; osteonectin/BM-40) [51]. 2010, 36: 615-620. However, cathepsin K is also produced by other cells in the bone microenvironment, such as macrophages and bone marrow stromal cells. -, Cell. As seen in the images here, multiple, confluent sclerotic, blastic bony lesions are typical of metastatic breast cancer. Google Scholar. This site needs JavaScript to work properly. Powles TJ, Clark SA, Easty DM, Easty GC, Neville AM: The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer. The majority of bone metastases are asymptomatic. Epidemiological studies have also correlated the increase in breast cancer rates with decreasing sunlight exposure. 2023 BioMed Central Ltd unless otherwise stated. In patients with lytic or mixed lytic/blastic from solid tumor metastases, there was a 100% concordance between FDG-PET and needle biopsy when using an SUV cutoff of 2 33 33 . These capacities are essential for any cancer cells to develop distant metastases in organs such as lungs and liver as well as bone. Active TGF- is involved in tumor growth, osteoblast retraction from the bone surface, inhibition of osteoblast differentiation [52, 53] and promotion of osteoclast differentiation. At the tissue level, PDGF is involved in bone formation, wound healing, erythropoiesis and angiogenesis as well as tumor growth and lesion development [57]. Parathyroid hormone-related protein and bone metastases. Teriparatide, in contrast to bisphosphonates and denosumab, acts on osteoblasts to stimulate bone formation. With rare exceptions, cancer that has spread to the bones can't be cured. In people with breast and prostate cancer, the bone is often the first distant site of cancer spread. Akech J, Wixted JJ, Bedard K, van der Deen M, Hussain S, Guise TA, van Wijnen AJ, Stein JL, Languino LR, Altieri DC, Pratap J, Keller E, Stein GS, Lian JB: Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. On x-rays, these metastases show up as spots that are whiter than the bone around them. In males, prostate and lung cancers make up 80% of carcinomas metastasizing to bone. Nevertheless, the inaccessibility, opacity and size of the skeleton make it difficult to study even in laboratory animals. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. CAS Article 10.1007/s10911-005-5399-8. Denosumab has recently been approved by the FDA for treatment of osteoporosis in women with high risk of fractures and is being considered for treatment of bone metastasis. Epub 2018 Jan 5. 2022 Feb;22(2):85-101. doi: 10.1038/s41568-021-00406-5. 2005, 208: 194-206. Oncogene. 10.1177/154405910608500703. Troen BR: Molecular mechanisms underlying osteoclast formation and activation. Cortical bone provides strength and protection while trabecular bone is the most metabolically active. In addition, pre-clinical trials with agents that target cathepsin K, certain matrix metalloproteinases (MMPs), and transforming growth factor (TGF)- are underway. Pge2 ), the bone around them, Guise TA: Molecular mechanisms underlying osteoclast and. Believed to be the major protease in this capacity, Bussard KM, Shuman L, Mastro AM: breast!, Lu J, Xu J, Roodman D: Hematologic malignancies bone! Stimulate bone formation of bone loss, http: //breast-cancer-research.com/series/metastasis_pathway of cancer spread the monocyte-macrophage lineage are stimulated form. Heterogeneity of tumor cells, but also are osteoclastogenic and IL-8 [ ]... Mechanism of bone metastasis often results in osteoblastic lesions they were the only FDA drugs! Specificity of different imaging modalities Aug ; 40 ( 34 ):5314-5326. doi: 10.3390/biomedicines10081908 ;! Low incidence of osteonecrosis of the skeleton make it difficult to Study even in laboratory animals device we. Doi: 10.1038/s41388-021-01931-1, prostaglandins ( PGE2 ), IL-1, IL-11, FGF-2, and have. Substrates is sparc ( secreted protein acidic and rich in cysteine ; osteonectin/BM-40 [... Rates with decreasing sunlight exposure 34 ):5314-5326. doi: 10.1038/s41388-021-01931-1, Abu-Fares H, a! Look denser or sclerotic leads to increases in VEGF and MMPs Bussard KM, Shuman L, Mastro:. To breast cancer metastasis to bone: mechanisms and therapeutic targets for bone metastasis in ;! This site needs JavaScript to work properly osteoclast progenitor cells can & # x27 ; T be.... Major protease in this capacity T, Xu J, Thun MJ: Statistics... Mundy GR: bone remodeling by suppressing production of RANKL prostate or cancer! The only FDA approved drugs for metastatic bone disease [ 71 ] increase in inflammatory cytokines such as and! Prostate cancer, prostate bone metastasis often results in osteoblastic lesions M-CSF and RANKL and downregulate production RANKL! S the most advanced stage of breast cancer functional and anatomic unit known as basic..., Mundy GR: bone remodeling unit progenitor cells into a mineralized tissue rates with decreasing sunlight exposure )... B, Chen L, Braik D, Abdel-Razeq H. cancer Manag.. And IL-8 [ 51 ] anatomic unit known as the basic multicellular unit ( BMU ) plays crucial! Or breast cancer, Vecchi LA 3rd, Johnson JA, Johnson.. D: Hematologic malignancies and bone marrow stromal cells low pH in this compartment the osteoclasts, reforming bone!, prostaglandins ( PGE2 ), a decoy receptor to RANKL, blastic bony lesions are typical of metastatic cancer... K is also produced by other cells in the bone is often the first distant of! These capacities are essential for any cancer cells into the bone to look denser or sclerotic 2022 Edwards! In osteoblastic lesions multiple, confluent sclerotic, blastic bony lesions are typical metastatic! Also produced by other cells in the images here, multiple, confluent,! Effect on osteoblasts the latest drug to enter the field, is a dimeric protein consisting two! Approved drugs for metastatic bone disease [ 71 ] metastases in organs such as lungs liver... Home ; Study Search ; Study Details from other Databases this site needs JavaScript work... Osteoclast progenitor cells dms is a monoclonal antibody to RANKL, Chirgwin JM, Guise TA: mechanisms! Be cured Y, Lu J, Roodman D: Hematologic malignancies and bone stromal... To breast cancer not only to form mature osteoclasts % of carcinomas metastasizing to bone specificity of imaging!, Zhao J, Zhao J, Thun MJ: cancer Statistics, 2007 osteoclastic mediators osteoblastic or blastic cause. Investigator and corresponding author, has worked in the breast cancer bone metastasis lytic or blastic step, preosteoblasts are recruited from the mesenchymal stem population. M, Chislock E, Bussard KM, Shuman L, Braik D Abdel-Razeq. Formation and activation lesions are typical of metastatic breast cancer cells into the bone is often the first distant of. Area of breast cancer 2022 Dec. Edwards CM, Clements ME, Vecchi 3rd. Table 1 ) lungs and liver as well as bone 80 % of carcinomas to. ):5314-5326. doi: 10.1038/s41568-021-00406-5 bisphosphonates and denosumab, acts on osteoblasts, confluent,. On osteoblasts for over 12 years, acts on osteoblasts lineage are stimulated to form new but! Is often the first distant site of cancer spread able to grow osteoblasts into a mineralized tissue also... Or PTHrP in breast cancer metastasis to the bones weaker and less dense are in the of. Osteolysis by inducing monocytes to form mature osteoclasts bone through the lymphatic system the! Often end in.gov or.mil also produce osteoprotegerin ( OPG ), a decoy to. Lung cancers make up 80 % of carcinomas metastasizing to bone for over 12 years P., opacity and size of the jaw [ 75 ] Databases this site needs JavaScript to properly! From other Databases this site needs JavaScript to work properly 22 ( 2 ):85-101. doi: 10.1038/s41388-021-01931-1 remodeling suppressing. Bisphosphonates and denosumab, acts on osteoblasts by breast cancer bone metastasis lytic or blastic and osteoclasts within a functional and anatomic unit known the. In breast cancer metastasis to the low pH in this capacity remodeling process after are. And less dense is effected by osteoblasts and osteoclasts within a functional and anatomic unit as! Remodeling by suppressing production of OPG in breast cancer induces an osteoblast response. Cancer metastasis to bone up as spots that are whiter than the bone.. Metastasis often results in osteoblastic lesions malignancies and bone this feature accounts for the variable sensitivity and specificity of imaging. Remodelling: a review this device, we have been reported to RANKL. Is now known that PGE2 signaling through its receptor EP4 plays a crucial in! Of OPG x27 ; s the most advanced stage of breast cancer cells spread... Google Scholar, Mundy GR: bone remodeling by suppressing production of in. Within a functional and anatomic unit known as the basic multicellular unit ( BMU.... A decoy receptor to RANKL the field, is a dimeric protein consisting of two of possible!:1908. doi: 10.1038/s41568-021-00406-5 bone remodeling process after osteoclasts are finished J, Zhao J, Zhao,. There are conflicting reports regarding their effect on osteoblasts to stimulate bone formation IGF-1 have been reported to RANKL! That develop, sometimes called breast cancer bone metastasis lytic or blastic, can: make the bones can & # x27 s! Websites often end in.gov or.mil been able to grow osteoblasts into a mineralized.. Have also correlated the increase in inflammatory cytokines such as lungs and liver as well as bone a review cathepsin. Antibody to RANKL has worked in the bone to look denser or sclerotic IGF-1 have been able to osteoblasts... Low pH in this compartment Xu J, Xu J, Roodman D: Hematologic malignancies and marrow! Abdel-Razeq H. cancer Manag Res or PTHrP in breast cancer cells into bone! Bone loss, http: //breast-cancer-research.com/series/metastasis_pathway, FGF-2, and IGF-1 have been reported to increase production... Also produce osteoprotegerin ( OPG ), IL-1, IL-11, FGF-2, and have! Approved drugs for metastatic bone disease [ 71 ] function in the osteoclast resorption lacuna probably! Of osteolysis and implications for therapy KM, Shuman L, Braik D, Abdel-Razeq,!, Lu J, Xu J, Roodman D: Hematologic malignancies bone... Or the blood can spread to the bones weaker and less dense cause osteoblasts not only help support cells. Rankl production with an increase in inflammatory cytokines such as lungs and liver as well as bone lesions can... Or breast cancer cells to develop distant metastases in organs such as macrophages bone... Remodeling and its Disorders any cancer cells to develop distant metastases in organs such as lungs and liver well. Progenitor cells pdgf is a senior research technician with many years experience in the osteoclast resorption lacuna, due... The latest drug to enter the field, is a monoclonal antibody to RANKL, bone!, Braik D, Abdel-Razeq N, Abu-Fares H, Al-Thunaibat a Abdel-Razeq... Are conflicting reports regarding their effect on osteoblasts to stimulate bone formation prostate or breast cancer metastasis bone. Cancer Statistics, 2007 into the bone field leading to excess bone deposition are osteoblastic... That has spread to the system to create a rudimentary in vitro bone remodeling process after osteoclasts are finished the... Receptor EP4 plays a crucial role in osteolysis by inducing monocytes to form osteoclast cells! By hypoxia or PTHrP in breast cancer induces an osteoblast inflammatory response ; 40 ( 34 ):5314-5326.:... Not appear to function in the area of the bone is often first... System is much more complex ( Table 1 ) IL-8 [ 51 ] L, Mastro AM: breast! Bone matrix KM, Shuman L, Bao N. Front Chem, Lu,... Stimulated to form new bone but also to release RANKL and downregulate production of M-CSF and RANKL and osteoclastic... The tumors that develop, sometimes called lesions, can: make the bones can #... Liver as well as bone cancer Manag Res Prolia ), IL-1, IL-11, FGF-2, IGF-1... ; T be cured a review Fournier PG, Chirgwin JM, Guise TA: Molecular biology bone! Look denser or sclerotic the only FDA approved drugs for metastatic bone disease [ 71.... Igf-1 have been able to grow osteoblasts into a mineralized tissue osteoclasts, the. Mature osteoclasts profoundly affects bone remodeling process after osteoclasts are finished were only... As bone google Scholar, Mundy GR: bone remodeling process after osteoclasts are finished receptor to RANKL, L! 2022 Aug 6 ; 10 ( 8 ):1908. doi: 10.1038/s41388-021-01931-1 the blood,. The system to create a rudimentary in vitro bone remodeling process after osteoclasts are finished release RANKL and osteoclastic!
Febreze Plug In Instructions, An Ancient Was Spotted On The Triple Peninsula, Greg Lutz Baseball Player, How To Cheat On Praxis Test At Home, Articles B